APA (7th ed.) Citation

Llombart-Cussac, A., Prat, A., Pérez-García, J. M., Mateos, J., Pascual, T., Escrivà-de-Romani, S., . . . Cortés, J. (2024). Clinicopathological and molecular predictors of [18F]FDG-PET disease detection in HER2-positive early breast cancer: RESPONSE, a substudy of the randomized PHERGain trial. European Journal of Nuclear Medicine & Molecular Imaging, 51(9), 2733. https://doi.org/10.1007/s00259-024-06683-0

Chicago Style (17th ed.) Citation

Llombart-Cussac, Antonio, et al. "Clinicopathological and Molecular Predictors of [18F]FDG-PET Disease Detection in HER2-positive Early Breast Cancer: RESPONSE, a Substudy of the Randomized PHERGain Trial." European Journal of Nuclear Medicine & Molecular Imaging 51, no. 9 (2024): 2733. https://doi.org/10.1007/s00259-024-06683-0.

MLA (9th ed.) Citation

Llombart-Cussac, Antonio, et al. "Clinicopathological and Molecular Predictors of [18F]FDG-PET Disease Detection in HER2-positive Early Breast Cancer: RESPONSE, a Substudy of the Randomized PHERGain Trial." European Journal of Nuclear Medicine & Molecular Imaging, vol. 51, no. 9, 2024, p. 2733, https://doi.org/10.1007/s00259-024-06683-0.